Innate Pharma SA income statement

In fiscal 2025, Innate Pharma SA reported revenue of $10.2m, down 53.2% on the year before, operating income of −$61.1m (a -599.8% margin) and net income of −$55.6m, or −$0.62 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Innate Pharma SA: income statement, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	50	111	96	80	29	61	67	22	10
Research and development	76	82	70	57	56	54	61	56	49
Operating income	−45	6	2	1	−57	−60	−14	−56	−61
Interest expense	0	0	0	0	0	0	1	1	0
Income before tax	−54	3	9	−1	−54	−61	−8	−54	−56
Income tax	0	−0	0	0	0	0	0	0	0
Net income	−55	4	−23	−73	−62	−61	−8	−54	−56
Diluted EPS	−$1.01	$0.06	−$0.35	−$0.92	−$0.78	−$0.77	−$0.10	−$0.66	−$0.62
Diluted shares (average)	54m	59m	67m	79m	80m	80m	80m	81m	90m
EBITDA	−40	15	17	12	−51	−56	−8	−54	−59

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRBU vs IPHA IPHA vs RLAY IPHA vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Innate Pharma SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Innate Pharma SA.